Zai Lab (NASDAQ:ZLAB) CFO Yajing Chen Sells 619 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CFO Yajing Chen sold 619 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $25.00, for a total value of $15,475.00. Following the sale, the chief financial officer directly owned 35,072 shares of the company’s stock, valued at $876,800. This represents a 1.73% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Yajing Chen also recently made the following trade(s):

• On Friday, June 26th, Yajing Chen sold 2,264 shares of Zai Lab stock. The stock was sold at an average price of $17.46, for a total value of $39,529.44.

Zai Lab Price Performance

Shares of ZLAB stock traded up $0.54 during trading hours on Thursday, reaching $26.03. 1,041,801 shares of the company traded hands, compared to its average volume of 843,216. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $36.77. The company has a market cap of $2.96 billion, a P/E ratio of -15.22 and a beta of 0.78. The firm has a 50-day moving average price of $19.22 and a 200 day moving average price of $19.39.

Zai Lab (NASDAQ:ZLAB) last announced its quarterly earnings data on Tuesday, June 30th. The company reported ($0.50) earnings per share (EPS) for the quarter. The company had revenue of $106.31 million for the quarter. Zai Lab had a negative net margin of 41.86% and a negative return on equity of 27.43%. Sell-side analysts predict that Zai Lab Limited Unsponsored ADR will post -2.17 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Zai Lab stock. Royal Bank of Canada boosted its holdings in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. 41.65% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently issued reports on ZLAB shares. Citigroup increased their price objective on shares of Zai Lab from $44.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Wall Street Zen cut shares of Zai Lab from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings raised shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. Finally, Zacks Research upgraded Zai Lab from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zai Lab has a consensus rating of “Moderate Buy” and an average target price of $40.20.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.